阿加曲班序贯于巴曲酶治疗急性缺血性卒中的临床观察

Effects of Argatroban Combined with Batroxobin on Treating Patients with Acute Ischemic Stroke

目的:评价阿加曲班注射液序贯于巴曲酶治疗急性脑梗死的有效性和安全性。方法:急性脑梗死患者72例随机分为巴曲酶组及联合治疗组,各36例;巴曲酶组,在常规治疗基础上增加巴曲酶治疗;联合治疗组在常规治疗基础上给予阿加曲班序贯于巴曲酶治疗。分别于治疗前、治疗后3、7、10、14及21 d测定各组纤维蛋白原(FIB)、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)及欧洲卒中量表(ESS)评分。结果:治疗后7、10及14 d,联合治疗组FIB均低于巴曲酶组(P<0.05);治疗后7及10 d,联合治疗组PT、APTT明显长于巴曲酶组(P<0.01),14 d时,长于巴曲酶组(P<0.05)。治疗后10 d,联合治疗组ESS评分高于巴曲酶组(P<0.05);治疗后14及21 d,显著高于巴曲酶组(P<0.01)。2组均未见明显不良反应。结论:阿加曲班注射液序贯于巴曲酶治疗急性脑梗死安全、有效。

Objective： To evaluate the effects and safety of argatroban combined with batroxobin on treating patients with acute ischemic stroke.Methods： Seventy-two patients with acute ischemic stroke were randomly divided into batroxobin treatment group and combined treatment group.The patients in the batroxobin treatment group were treated with batroxobin treatment in addition to routine treatment,and in the combined treatment group with argatroban combined with batroxobin.The fibrinogen（FIB）,prothrombin time（PT）,active partial thromboplastin time（APTT） were detected and European Stroke Scale（ESS） were used to assess the neurologic impairment of patients at beginning and 3,7,10,14,and 21 days after treatment.Results： Level of FIB in the combined treatment group was lower than that in the batroxobin treatment group at 7,10,and 14 days post treatment（P〈0.05）.PT and APTT in the combined treatment group were significantly longer than those in the batroxobin treatment group at 7 and 10 days post treatment（P〈0.01） and longer than that in the batroxobin treatment group at 14 days post treatment（P〈0.05）.ESS score in the combined treatment group was higher than that in the batroxobin treatment group at 10 days post treatment（P〈0.05） and significantly higher than those in the batroxobin treatment group at 14 and 21 days post treatment（P〈0.01）.No adverse reactions were detected in the both groups.Conclusion： Argatroban combined with batroxobin is an effective and safe treatment for patients with acute ischemic stroke.